Edmonton, AB, September 14, 2021
To view the full announcement, including downloadable images, bios, and more, click here.
- PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
- Upcoming enrollment of 20-30 patients to begin at the Cross Cancer Institute in Edmonton and expand to Princess Margaret Hospital in Toronto and the BC Cancer Agency in Vancouver.
- This open label, dose escalation study will examine the safety and tolerability of PCLX-001.
Click image above to view full announcement.
Michael Weickert Ph.D
Distributed by: Reportable, Inc.